(19)
(11) EP 4 493 587 A1

(12)

(43) Date of publication:
22.01.2025 Bulletin 2025/04

(21) Application number: 23715415.8

(22) Date of filing: 14.03.2023
(51) International Patent Classification (IPC): 
C07K 16/18(2006.01)
A61P 35/00(2006.01)
C07K 14/725(2006.01)
C07K 16/30(2006.01)
A61K 39/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/4631; A61K 39/4611; A61P 35/00; C07K 2317/622; C07K 2319/03; C07K 16/18; C07K 16/30; C07K 14/4702
(86) International application number:
PCT/EP2023/056397
(87) International publication number:
WO 2023/174897 (21.09.2023 Gazette 2023/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 14.03.2022 EP 22161839

(71) Applicants:
  • Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    85764 Neuherberg (DE)
  • Eximmium Biotechnologies GmbH
    81377 Munich (DE)
  • Klinikum der Universitaet Muenchen
    81377 Munich (DE)

(72) Inventors:
  • ZEIDLER, Reinhard
    82140 Olching (DE)
  • GAERTNER, Kathrin
    81547 Munich (DE)

(74) Representative: Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB 
Ganghoferstraße 68 B
80339 München
80339 München (DE)

   


(54) COMPOSITION COMPRISING AN ANTIBODY WHICH BINDS TO HUMAN SRRM2 PRESENT ON THE CELL SURFACE OF A TARGET CELL